Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP < 90 mmHg compared to 33.2% of patients on irbesartan (p = 0.0005).
62 rühmas saavutas ravieesmärgi, SeDBP < 90 mmHg enne ravimi manustamist, 47, 2% patsientidest võrreldes 33, 2% irbesartaani rühmas (p = 0, 0005).